Active-duty U.S. service members filled more prescriptions for erectile dysfunction medications in 2025 than in any previously recorded year, Defense Health Agency data obtained through a Freedom of Information Act request reveals. The new record, 108,332 prescriptions, edges past the prior high of 108,323 set just one year earlier, and marks a 16.5 percent increase over the 92,996 prescriptions recorded in 2021.
The figures, first reported by the New York Post's James Franey, cover only active-duty troops. When retirees, veterans, and eligible military dependents are included, the broader military community filled 639,355 ED prescriptions in 2025, up from 627,121 the year before.
The Pentagon did not respond to the Post's request for comment on the prescription trends and has not connected the numbers to any broader health or readiness initiative.
Generic medications dominate the market. Over the past five years, generics accounted for 97.8 percent of all ED prescriptions filled across the military system. Brand-name Viagra and Cialis recorded zero active-duty prescriptions in both 2024 and 2025.
Among active-duty personnel in 2025, generic sildenafil citrate, the chemical equivalent of Viagra, led with 85,244 prescriptions. Tadalafil, the generic form of Cialis, accounted for another 22,880. A smaller number of troops, 197, received prescriptions for the injectable medication Edex.
The retiree and veteran population drove even larger volumes. In 2025, that group filled 268,678 sildenafil prescriptions and 221,940 tadalafil prescriptions. The sheer scale of those numbers reflects the size and age profile of the broader military benefits population, but the active-duty figures, drawn from a younger cohort, are the ones drawing attention.
The trajectory is clear: from 92,996 active-duty prescriptions in 2021 to 108,323 in 2024 to 108,332 in 2025. What the data does not reveal is whether the increase was steady year over year or whether there were dips in the intervening period. The FOIA records, as reported, do not include figures for 2022 or 2023.
Nor does the data explain why the numbers have climbed. The Defense Health Agency's records track prescriptions filled, not diagnoses. Whether the rise reflects changing medical practice, reduced stigma, broader access through military pharmacies, or shifts in force demographics remains an open question, one the Pentagon has not addressed.
The administration has focused its military efforts on recruiting, retention, and readiness. The House Armed Services Committee recently advanced a $1.15 trillion defense spending bill with bipartisan support, underscoring the scale of investment flowing toward the armed forces.
One detail worth noting: taxpayers are not footing the bill for brand-name pills. The near-total shift to generics, 97.8 percent over five years, with zero brand-name Viagra or Cialis prescriptions among active-duty troops in 2024 or 2025, means the per-prescription cost is a fraction of what it would have been a decade ago. Generic sildenafil can cost as little as a few dollars per dose through military pharmacy channels.
That matters in a defense budget context. ED medications have drawn political scrutiny in past years, with critics questioning whether taxpayer dollars should cover them at all. The generic shift largely neutralizes the cost argument, though the volume of prescriptions, more than 639,000 across the full military community, still represents a measurable line item.
Defense Secretary Pete Hegseth has made troop readiness a visible priority. He recently visited Guantanamo Bay and told troops to prepare for "any possible contingency" on Cuba, signaling the administration's emphasis on operational preparedness across the force.
The Post noted that sildenafil can be prescribed to women for certain cardiovascular conditions and suggested that the volume of prescriptions "suggests many were filled for male spouses of service members." That is an inference by the Post, not a conclusion drawn from the Defense Health Agency data. The FOIA records, as reported, do not break down prescriptions by the sex of the recipient.
Several other questions remain unanswered. The data does not specify whether prescriptions filled overseas, on deployments or at foreign installations, are included in the totals. It does not clarify whether the retiree and veteran figures also capture eligible dependents. And the five-year window for the generic-drug statistic is described only in relative terms, leaving the exact start year ambiguous.
The broader military posture under the current administration has extended well beyond domestic readiness. Saudi Arabia and Kuwait have quietly reopened bases to U.S. forces, and allied nations have stepped up cooperation in response to American pressure.
ED prescriptions are one small window into military healthcare, but they reflect something real about the force. The active-duty military skews young, the vast majority of service members are under 40. A rising prescription count in that population raises legitimate medical questions that the Pentagon has so far declined to address publicly.
Possible explanations range from the mundane to the meaningful. Military healthcare providers may simply be more willing to prescribe. Troops may feel less reluctance to ask. Deployment cycles, stress, and the physical toll of service all play documented roles in sexual health. Or the numbers may partly reflect administrative changes in how prescriptions are tracked and filled.
Without a Pentagon explanation, the data sits in a vacuum, interesting, verifiable, but incomplete.
Meanwhile, the administration continues to build out its national security team. President Trump recently nominated retired Oklahoma trooper Lance Schroyer to lead ICE, part of a broader pattern of placing experienced law enforcement figures in key roles.
The Defense Health Agency released the raw prescription data in response to the Post's FOIA request. But the Pentagon, referred to in the Post's reporting as "the War Department," an archaic term for the Department of Defense, offered no context, no explanation, and no comment on what the trends might mean for troop health or military readiness.
That silence is itself a data point. Federal agencies routinely provide background context when releasing health statistics. The decision not to comment leaves the interpretation entirely to outside observers, and to the inevitable political spin that follows any story touching the intersection of government spending, military culture, and personal health.
The numbers are what they are: 108,332 active-duty prescriptions in 2025, a record by nine. The trend line points up. The cost to taxpayers stays low thanks to generics. And the Pentagon has nothing to say about any of it.
When the government collects the data, releases it under FOIA, and then refuses to explain it, the public is left to draw its own conclusions. That's not transparency, it's a document dump without accountability.